177
Views
10
CrossRef citations to date
0
Altmetric
Research Paper

Tailored dose baclofen in patients with alcoholic liver disease: A case series with 2-year follow-up of hospitalisation

, , , , , , , & show all
Pages 510-517 | Received 29 Nov 2014, Accepted 08 Apr 2015, Published online: 08 May 2015

References

  • Addolorato, G., Caputo, F., Capristo, E., Domenicali M., Bernardi M., Janiri L., … Gasbarrini, G. (2002). Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study. Alcohol Alcohol, 37, 504–508
  • Addolorato, G., Leggio, L., Ferrulli, A., Cardone, S., Vonghia, L., Mirijello, A., … Gasbarrini, G. (2007). Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol dependent patients with liver cirrhosis: Randomised, doubleblind controlled study. Lancet, 370, 1915–1922
  • Addolorato, G., Leggio, L., Ferrulli, A., Cardone, S., Bedogni, G., Caputo, F., … Landolfi R. (2011). Baclofen Study Group: Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: Secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol, 46, 312–317
  • Agabio, R., Preti, A., & Gessa, G.L. (2013). Efficacy and tolerability of baclofen in substance use disorders: A systematic review. European Addiction Research, 19, 325–345
  • Ameisen O. (2005). Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: A self-case report of a physician. Alcohol Alcohol, 40, 147–150
  • Atkinson, M.J., Sinha, A., Hass, S.L., Colman, S.S., Kumar, R.N., Brod, M., & Rowland, C.R. (2004). Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health and Quality of Life Outcomes, 2, 12
  • Bohn, M.J., Krahn, D.D., & Staehler, B.A. (1995). Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcoholism: Clinical and Experimental Research, 19, 600–606
  • Bucknam W. (2007). Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol Alcohol, 42, 158–160
  • Dore, G.M., Lo, K., Juckes, L., Bezyan, S., & Latt, N. (2011). Clinical experience with baclofen in the management of alcohol-dependent patients with psychiatric comorbidity: A selected case series. Alcohol Alcohol, 46, 714–720
  • Beaurepaire, R. (2014). The use of very high-doses of baclofen for the treatment of alcohol-dependence: A case series. Frontiers in Psychiatry, 5, 143
  • Enserink, M. (2011). Addiction research. Anonymous alcoholic bankrolls trial of controversial therapy. Science, 332, 653
  • Froestl, W. (2011). A historical perspective on GABAergic drugs. Future Medicinal Chemistry, 3, 163–175
  • Garbutt, J.C., Kampov-Polevoy, A.B., Gallop, R., Kalka-Juhl, L., & Flannery, B.A. (2010). Efficacy and safety of baclofen for alcohol dependence: A randomized, double-blind, placebo-controlled trial. Alcohol Clinical Experimental Research, 34, 1849–1857
  • Heydtmann, M. (2011). Baclofen effect related to liver damage. Alcohol Clinical Experimental Research, 35, 848
  • Heydtmann, M., & McDonald, S.A. (2013). Survival and re-admission of patients admitted with alcoholic liver disease to a West of Scotland hospital. Scottish Medical Journal, 58, 134–138
  • Kumar, K., Sharma, S., Kumar, P., & Deshmukh, R. (2013). Therapeutic potential of GABA(B) receptor ligands in drug addiction, anxiety, depression and other CNS disorders. Pharmacology Biochemistry and Behavior, 110, 174–184
  • Leggio, L., Garbutt, J.C., & Addolorato, G. (2010). Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS & Neurological Disorders – Drug Targets, 9, 33–44
  • Leggio, L., Ferrulli, A., Zambon, A., Caputo, F., Kenna, G.A., Swift, R.M., & Addolorato, G. (2012). Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addictive Behaviors, 37, 561–564
  • Leggio, L., Zywiak, W.H., McGeary, J.E., Edwards, S., Fricchione, S.R., Shoaff, J.R., … Kenna, G.A. (2013). A human laboratory pilot study with baclofen in alcoholic individuals. Pharmacology Biochemistry and Behavior, 103, 784–791
  • Levy, L.M., & Degnan, A.J. (2013). GABA-based evaluation of neurologic conditions: MR spectroscopy. American Journal of Neuroradiology, 34, 259–265
  • Lyon, J.E., Khan, R.A., Gessert, C.E., Larson, P.M., & Renier, C.M. (2011). Treating alcohol withdrawal with oral baclofen: A randomized, double-blind, placebo-controlled trial. Journal of Hospital Medicine, 6, 469–474
  • Malet, L., Llorca, P.M., Beringuier, B., Lehert, P., & Falissard, B. (2006). ALQOL 9 for measuring quality of life in alcohol dependence. Alcohol Alcohol, 41, 181–187
  • Miller, W.R. (1995). The drinker inventory of consequenses: An instrument for assessing adverse consequences of alcohol abuse. Maryland: National Institute of Health
  • Morley, K.C., Baillie, A., Leung, S., Addolorato, G., Leggio, L., & Haber, P.S. (2014). Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol Alcohol, 49, 654--660
  • Muzyk, A.J., Rivelli, S.K., & Gagliardi, J.P. (2012). Defining the role of baclofen for the treatment of alcohol dependence: A systematic review of the evidence. CNS Drugs, 26, 69–78
  • Olsen, R.W. (2002). Chapter 12 -- GABA. In K.L. Davis, D. Charney, J.T. Coyle, & C. Nemeroff (Eds.), Neuropsychopharmacology: The fifth generation of progress (pp. 159–168). American College of Neuropsychopharmacology
  • Pastor, A., Jones, D.M., & Currie, J. (2012). High-dose baclofen for treatment-resistant alcohol dependence. Journal of Clinical Psychopharmacology, 32, 266–268
  • R Development Core Team. (2011). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. Retrieved from: http://www.R-project.org/
  • Rigal, L., Alexandre-Dubroeucq, C., de Beaurepaire, R., Le Jeunne, C., & Jaury, P. (2012). Abstinence and ‘low-risk’ consumption 1 year after the initiation of high-dose baclofen: A retrospective study among ‘high-risk’ drinkers. Alcohol Alcohol, 47, 439–442
  • Rolland, B., Bordet, R., & Cottencin, O. (2012). Alcohol-dependence: The current French craze for baclofen. Addiction, 107, 848–849
  • Rolland, B., Paille, F., Fleury, B., Cottencin, O., Benyamina, A., & Aubin, H.J. (2014). Off-label baclofen prescribing practices among french alcohol specialists: Results of a national online survey. PLoS One, 9, e98062
  • WHO. (2007). ICD10: International Statistical Classification of Diseases and Related Health Problems 10th Revision, Version for 2007. Retrieved from: http://apps.who.int/classifications/apps/icd/icd10online2007/
  • Yamini, D., Lee, S.H., Avanesyan, A., Walter, M., & Runyon, B. (2014). Utilization of baclofen in maintenance of alcohol abstinence in patients with alcohol dependence and alcoholic hepatitis with or without cirrhosis. Alcohol Alcohol, 49, 453–456
  • Zigmond, A.S., & Snaith, R.Pc. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67, 361–370

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.